All In Biotech

Free tool

FAERS Monitor: Hylenex Recombinant

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 021859 or its brand name (Hylenex Recombinant, Hyaluronidase Recombinant Human). Reports on generic versions are filed under their own applications.

Reports

1,227

Serious

1,022

83% of reports

Hospitalization

708

Death reported

548

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue305
  • abdominal discomfort298
  • alopecia294
  • diarrhoea282
  • asthenia281
  • arthralgia280
  • headache279
  • hypertension279
  • hypersensitivity278
  • hepatic enzyme increased275
  • contusion271
  • asthma270
  • blood cholesterol increased268
  • discomfort267
  • dyspnoea267

Reports by year received

View as table
YearReports
20048
20058
200622
200727
20088
20099
20106
20118
20125
20132
201414
201545
201623
201731
201823
201929
202053
202167
202261
2023110
2024310
2025232
2026126

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,932 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
blood cholesterol increasedSignal26899.189.125,840
discomfortSignal26775.367.719,482
hepatic enzyme increasedSignal27569.462.518,462
contusionSignal27148.443.512,550
asthmaSignal27041.036.910,541
abdominal discomfortSignal29830.527.68,527
hypersensitivitySignal27825.723.26,626
alopeciaSignal29425.723.37,009
hypertensionSignal27922.620.45,792
astheniaSignal28112.811.63,104
arthralgiaSignal28011.610.42,740
dyspnoeaSignal2678.17.31,696
headacheSignal2797.66.91,649
diarrhoeaSignal2827.56.81,629
fatigueSignal3056.76.11,535

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.